Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Accumulated Expenses (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Accumulated Expenses for 11 consecutive years, with $49.9 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 107.11% to $49.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.9 million through Dec 2025, up 107.11% year-over-year, with the annual reading at $49.9 million for FY2025, 107.11% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $49.9 million at Intellia Therapeutics, up from $40.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $67.0 million in Q4 2023, with the low at $10.0 million in Q2 2021.
  • Average Accumulated Expenses over 5 years is $29.9 million, with a median of $22.6 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses surged 568.82% in 2021, then crashed 64.98% in 2023.
  • Over 5 years, Accumulated Expenses stood at $43.3 million in 2021, then soared by 40.56% to $60.9 million in 2022, then increased by 10.09% to $67.0 million in 2023, then tumbled by 64.08% to $24.1 million in 2024, then surged by 107.11% to $49.9 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $49.9 million, $40.8 million, and $12.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.